Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 0.66 |
| ▸ | CNR2 | P34972 | 5/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5238111 | 0.83 | CNR1 (0.69) | CNR1CNR2KDM4ESMN1; SMN2MAPT | |
| SCHEMBL5236479 | 0.82 | CNR1 (0.73) | CNR1CNR2KDM4ESMN1; SMN2MAPT | |
| SCHEMBL5236233 | 0.82 | CNR1 (0.67) | CNR1CNR2KDM4ESMN1; SMN2MAPT | |
| SCHEMBL5159484 | 0.80 | CNR1 (0.71) | CNR1CNR2KDM4ESMN1; SMN2MAPT | |
| SCHEMBL5164108 | 0.80 | CNR1 (1.00) | CNR1CNR2ALDH1A1CYP2C9 | |
| SCHEMBL5256886 | 0.78 | TSHR (0.58) | KDM4EBACE1POLBLMNAALDH1A1 | |
| SCHEMBL4195045 | 0.77 | MEN1 (0.57) | CNR1CNR2KDM4ESMN1; SMN2BACE1 | |
| SCHEMBL5232573 | 0.76 | CNR1 (0.70) | CNR1CNR2KDM4ESMN1; SMN2MAPT | |
| SCHEMBL5230358 | 0.76 | CNR1 (0.72) | CNR1CNR2KDM4ESMN1; SMN2MAPT | |
| SCHEMBL19422863 | 0.76 | MAPT (1.00) | KDM4ESMN1; SMN2MAPTALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225292-A1 | Therapeutic Compounds: Pyridine as Scaffold | ASTRAZENECA AB (SE) | 2007-09-27 | — | — | US | claimed |
| EP-1756060-A1 | THERAPEUTIC COMPOUNDS: PYRIDINE AS SCAFFOLD | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | claimed |
| WO-2005115986-A1 | THERAPEUTIC COMPOUNDS: PYRIDINE AS SCAFFOLD | ASTRAZENECA AB (SE) | 2005-12-08 | — | — | WO | claimed |
| US-20070225292-A1 | Therapeutic Compounds: Pyridine as Scaffold | ASTRAZENECA AB (SE) | 2007-09-27 | — | — | US | disclosed |
| US-20070225292-A1 | Therapeutic Compounds: Pyridine as Scaffold | ASTRAZENECA AB (SE) | 2007-09-27 | — | — | US | disclosed |
| US-20070225292-A1 | Therapeutic Compounds: Pyridine as Scaffold | ASTRAZENECA AB (SE) | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225292-A1 | Therapeutic Compounds: Pyridine as Scaffold | OPRL1, OPRK1, P2RX3 | CNR1 6/4885CNR2 11/4885KDM4E 2218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.